Home2024-01-30T15:04:25+01:00

BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure

0
Partners
0
Duration
0
EU Contribution

Project

The innovation potential of BIOTOOL-CHF is built on the overall approach that will be adopted to tackle the unsolved issue of improving the efficiency of fluid management in systolic heart failure

Objectives

BIOTOOL-CHF will discover, develop, and validate a personalised approach to manage diuretic therapy in heart failure and reduced ejection fraction, to reduce heart failure hospitalizations and improve quality of life

Impacts

BIOTOOL-CHF gathers major European heart failure and big data analysis experts to provide an innovative approach to the management patients with heart failure and reduced ejection fraction, which is one of the most frequent, costly and deadly pathological conditions in Europe

RecentNews

Forthcoming Events

Recent Tweets

PARTNERS INVOLVED

BIOTOOL-CHF partners join forces to change the paradigm of heart failure with reduced ejection fraction pharmacological therapy, by developing a personalised strategy to target congestion with diuretics.

Project Details

PROJECT NUMBER: 101095653
PROJECT TITLE: BIOmarker based diagnostic TOOLkit to personalize pharmacological approaches in congestive heart failure
TOPIC: HORIZON-HLTH-2022-TOOL-11-01
START DATE: 1 October 2023
DURATION: 60 Months
GRANTING AUTHORITY: HADEA
EU CONTRIBUTION: 9.600.663,00 Euro

Follow Us!

“Funded by the European Union. Views and opinions expressed are however those of the author(s) only and do notnecessarily reflect those of the European Union or the European Health and Digital Executive Agency (HADEA). Neither the European Union nor the granting authority can be held responsible for them.”

Copyright 2023 BIOTOOL-CHF | All Rights Reserved | Powered by WarrantHub S.p.A.

Go to Top